Recent Updates
Recently added Catalysts
PRLD Neutral Sentiment

Discovery of precision degrader antibody conjugates (pDACs) employing novel SMARCA2/4 degrader payloads

Sunday, March 15, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses the discovery of precision degrader antibody conjugates (pDACs) utilizing novel SMARCA2/4 degrader payloads. This development is part of Prelude Therapeutics' ongoing research efforts in targeted therapies. The focus is on advancing their pipeline and enhancing treatment options for specific cancer types.
Price reaction · baseline $3.3 (2026-03-13 close) · 2 other PRLD headline(s) in the window, move may be shared
day 0 close · peak
+1.8%

Market Sentiment Analysis

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+217%
120-day peak, hindsight
Typical move
8.2%
average across 4 past catalysts
Cash runway
~29 mo
Minimal dilution risk
Lead asset
PRT1419
Phase 1 · Multiple Myeloma

Full Press Release Details

• About Overview Leadership Board of Directors
• Science Overview Pipeline JAK2V617F KAT6A Precision DACs Discovery Engine Publications
• Investors Overview News & Events News Releases Events & Presentations Financials SEC Filings Quarterly Results Stock Information Stock Quote & Chart Analysts Governance Governance Documents Leadership Committee Composition Investor Resources Investor Faqs Contact IR Email Alerts
• News
• Life at Prelude Overview Open Positions
• Contact
• Overview
• Leadership
• Board of Directors
• Overview
• Pipeline
• JAK2V617F
• KAT6A
• Precision DACs
• Discovery Engine
• Publications
• Overview
• News & Events News Releases Events & Presentations
• Financials SEC Filings Quarterly Results
• Stock Information Stock Quote & Chart Analysts
• Governance Governance Documents Leadership Committee Composition
• Investor Resources Investor Faqs Contact IR Email Alerts
• News Releases
• Events & Presentations
• SEC Filings
• Quarterly Results
• Stock Quote & Chart
• Analysts
• Governance Documents
• Leadership
• Committee Composition
• Investor Faqs
• Contact IR
• Email Alerts
• Overview
• Open Positions
Andrew W. Buesking, Sr. Director, Chemistry on behalf of the pDAC team
ShareAdd on Google
Tags: PRLD Viatris Investor Conferences Healthcare pDACs SMARCA2 SMARCA4 cancer therapies
Last updated: Mar 15, 2026

Biotech snapshot

Cash runway
$152M liquidity · $5M/mo burn
~29 mo
Minimal dilution risk
Lead asset
PRT1419Phase 1
Multiple Myeloma →

Catalyst track record

+217%
best trade around PRLD's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for PRLD.

See every catalyst's timing & PoA →